Harrow Health, Inc. ($HROW) reported its fourth-quarter and year-end 2024 audited financial results, highlighting an 84% increase in quarterly revenue compared to the previous year. The company's revenue growth is supported by a compound annual growth rate (CAGR) of 40% over the past decade. In addition, the company's Iheezo product exceeded consensus revenue estimates by 35% for the fourth quarter. However, analysts note that the first quarter is typically seasonally weak for both Iheezo and Vevye, suggesting that growth may not be expected in Q1 compared to Q2. Following the announcement, shares of Harrow rose by 10.7% in pre-market trading.